FDG PET of the Adrenals
DOWNLOAD FACT SHEET IN PDF

References:

1) Chong S, Lee KS, Kim HY. Integrated PET-CT for the Characterization of Adrenal Gland
Lesions in Cancer Patients: Diagnostic Efficacy and Interpretative Pitfalls. Radiographics 2006;
26:1811-1826 [PDF]

2) Elaini AB, Shetty SK, Chapman VM. Improved Detection and Characterization of Adrenal
Disease with PET-CT. Radiographics 2007;27:755-767 [PDF]

3) Yun M, Kim W, Alnafisi N. 18F-FDG PET in Characterizing Adrenal Lesions Detected on CT or
MRI. J Nucl Med 2001;42:1795-1799 [PDF]

4) Blake MA, Slattery JMA, Kalra MK. Adrenal Lesions: Characterization with Fused PET/CT
Image in Patients with Proved or Suspected Malignancy--Initial Experience. Radiology 2006;238
(3):970-977 [PDF]

5) Blake MA, Kalra MK. Collision Adrenal Tumors on PET/CT. AJR 2004;183:864-865 [PDF]

6) Bagheri B, Maurer AH, Cone L. Characterization of the Normal Adrenal Gland with 18F-FDG
PET/CT. J Nucl Med 2004;45:1340-1343 [PDF]

7) Shulkin BL, Koeppe RA, Francis IR. Pheochromocytomas That Do Not Accumulate
Metaiodobenzylguanidine: Localization with PET and Administrationo f FDG. Radiology 1993;
186:711-715 [PDF]

8) Rao SK, Caride VJ, Ponn R. F-18 Fluorodeoxyglucose Positron Emission Tomography-
Positive Benign Adrenal Cortical Adenoma: Imaging Features and Pathologic Correlation. Clin
Nucl Med 2004;29:300-302 [PDF]

9) Okada M, Shimono T, Komeya Y. Adrenal masses: the value of additional fluorodeoxyglucose-
positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between
benign and malignant lesions. Ann Nucl Med 2009;23:349-354 [PDF]

10) Tessonnier L, Sebag F, Palazzo FF. Does 18F-FDG PET/CT add diagnostic accuracy in
incidentally identified non-secreting adrenal tumours? European Journal of Nuclear Medicine
and Molecular Imaging 2008;35:2018-2025 [PDF]

11) Shulkin BL, Thompson NW, Shapiron B. Pheochromocytomas: Imaging with 2-[Fluorine-18]
fluoro-2-deoxy-D-glucose PET. Radiology 1999;212:35-41 [PDF]

12) Caoili EM, Korobkin M, Brown RK. Differentiating adrenal adenomas from nonadenomas
using (18)F-FDG PET/CT: quantitative and qualitative evaluation. Acad Radiol 2007;14:468-475
[PDF]

13) Jana S, Zhang T, Milstein DM. FDG-PET and CT characterization of adrenal lesions in cancer
patients. Eur J Nucl Med Mol Imaging 2006;33:29-35 [PDF]

14) Maurea S, Mainolfi C, Bazzicalupo L. Imaging of Adrenal Tumors Using FDG PET:
Comparison of Benign and Malignant Lesions. AJR 1999;173:25-29 [PDF]

15) Kumar R, Xiu Y, Yu JQ. 18F-FDG PET in Evaluation of Adrenal Lesions in Patients with Lung
Cancer. J Nucl Med 2004;45:2058-2062 [PDF]

16) Metser U, Miller E, Lerman H. 18F-FDG PET/CT in the Evaluation of Adrenal Masses. J Nucl
Med 2006;47:32-37 [PDF]

17) Shimizu A, Oriuchi N, Tsushima Y. High [18F] 2-fluoro-2-deoxy-D-glucose (FDG) uptake of
adrenocortical adenoma showing subclinical Cushing’s syndrome. Ann Nucl Med 2003;17(5):
403-406 [PDF]

18) Basu S, Nair N. 18F-FDG Uptake in bilateral adrenal hyperplasia causing Cushing’s
syndrome. Eur J Nucl Med Mol Imaging 2005;32:384 [PDF]

19) Becherer A, Vierhapper H, Potzi C. FDG-PET in Adrenocortical Carcinoma. Cancer
Biotherapy & Radiopharmaceuticals 2001;16(4):289-295 [PDF]

20) Rosenbaum SJ, Lind T, Antoch G. False-Positive FDG PET Uptake – the Role of PET/CT. Eur
Radiol 2006;16:1054-1065 [PDF]